Epocrates Inc. Announces Strategic
Investment by Goldman Sachs
Hudson Street Division to Offer Company’s Services
SAN MATEO, CALIF., January 7, 2008 - Epocrates, Inc., developer of clinical solutions for healthcare professionals, announced today that Goldman Sachs (NYSE: GS) has made a strategic investment in the company. The companies also entered into an agreement to co-market Epocrates’ market research services.
"As a leading developer of clinical research tools, Epocrates has emerged as one of the most recognized healthcare technology companies among physicians, and we are pleased to introduce its services to our clients," said Michael Sanders, Managing Director, Goldman, Sachs & Co., and head of Hudson Street.
More than 500,000 healthcare professionals use Epocrates’ mobile or web-based products at the point of care. The company’s software solutions feature drug, disease and diagnostic decision support tools that help physicians improve the quality of patient care and increase productivity. In addition, Epocrates recruits clinicians to participate in market research studies. Study topics range from assessing interest in new pharmaceutical compounds to understanding current disease treatment protocols.
"We have the largest, verified market research panel in the nation, including more than 145,000 opted-in physicians. We are looking forward to working with Hudson Street to serve the research needs of Goldman Sachs’ clients," said Kirk Loevner, chairman and chief executive officer of Epocrates.
As part of the agreement, Hudson Street, a Goldman Sachs business, will co-market Epocrates’ market research products and services to its institutional clients in the financial sector.
About Hudson Street Services
Hudson Street Services, a Goldman Sachs business, offers investment professionals access to a select platform of unique content and tools that can be integrated into their investment process. Collectively, Hudson Street Services offer a more flexible, more efficient way for clients to access critical information and ultimately make better investment decisions.
Erica Sniad Morgenstern
Epocrates Public Relations
PHONE: (650) 227-6907